Welcome to our dedicated page for AEON Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
AEON Biopharma, Inc. filed Pre-Effective Amendment No. 1 to its Form S-1 as an exhibits-only update. The company is filing an amended Calculation of Filing Fee Table (Exhibit 107) to reflect the proposed maximum aggregate offering price of Class A common stock underlying the Five-Year Milestone Warrants at 115% of the assumed public offering price and to pay the related incremental registration fee. The remainder of the registration statement is unchanged. The amendment also restates the exhibits list and includes signatures from the chief executive officer, other senior officers and the board of directors.
AEON Biopharma is registering 17,479,373 shares of common stock, together with pre-funded and milestone warrants, in a primary underwritten offering at an assumed price of $0.7151 per share. Net proceeds of about $11 million are expected, with an underwriters’ over-allotment option for additional securities.
The company develops ABP-450 as a biosimilar to BOTOX for therapeutic uses under the Section 351(k) pathway and plans to use proceeds mainly for working capital and comparative analytical testing to support biosimilarity. AEON reports an accumulated deficit of $482.6 million and has concluded there is substantial doubt about its ability to continue as a going concern without additional financing, with cash expected to fund operations only into the third quarter of 2026.
The offering includes two-year and five-year milestone warrants that can expire early if specific FDA meeting or Phase 3 trial milestones are announced, and may provide up to approximately $26.9 million in additional gross proceeds if fully exercised for cash. Investors face immediate dilution of about $0.83 per share at the assumed price, and there is no expected trading market for the warrants. AEON is also working to regain compliance with NYSE American stockholders’ equity listing standards while its common stock continues to trade under the symbol “AEON.”
Thunen Shelley B reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Shelley B. Thunen received an equity grant of 222,684 shares of Class A common stock in the form of restricted stock units. The award was granted on June 17, 2026 as compensation, at a grant price of $0.00 per share rather than an open-market purchase.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of AEON Biopharma’s 2027 annual stockholder meeting, subject to her continued service. Following this award, Thunen directly holds 258,705 shares of the company’s Class A common stock.
PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Robert J. Palmisano received an award of 222,684 restricted stock units (RSUs) of Class A Common Stock on June 17, 2026. The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the 2027 annual stockholders’ meeting, subject to continued service. Following this grant, his direct holdings total 258,705 shares.
Forth Marc reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Marc Forth reported an equity award of 222,684 shares of Class A Common Stock in the form of restricted stock units (RSUs). The RSUs were granted on June 17, 2026 at no cash price and represent compensation rather than an open-market purchase.
The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the date of the company’s 2027 annual meeting of stockholders, subject to his continued service. Following this award, Forth directly holds 973,231 shares of AEON Biopharma common stock.
FISCHER JOST reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Jost Fischer received an equity grant in the form of restricted stock units. The award covers 222,684 RSUs granted on June 17, 2026 at no cash cost, increasing his direct holdings to 489,469 shares of Class A Common Stock.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of AEON Biopharma’s 2027 annual meeting of stockholders, conditioned on his continued service through the applicable vesting date. This is a compensation-related grant rather than an open‑market share purchase.
Carter Eric G reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Eric G. Carter received an equity grant of 222,684 restricted stock units (RSUs) of Class A Common Stock. The award was granted on June 17, 2026 and carries no purchase price. The RSUs vest in full on the earlier of one year after the grant date or the 2027 annual stockholder meeting, subject to his continued service. Following this grant, Carter holds 258,705 shares directly.
AEON Biopharma, Inc. reported results from its Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Marc Forth and Seongsoo Park as Class III directors to terms ending at the 2029 annual meeting, with 13,297,322 and 13,117,299 votes "for," respectively.
Stockholders also ratified the appointment of KPMG LLP as AEON Biopharma’s independent registered public accounting firm for the fiscal year ended December 31, 2026, with 21,502,418 votes "for," 18,217 "against" and 1,498 "abstain."
AEON Biopharma, Inc. furnished a new corporate investor presentation on its website and via an exhibit to a current report. The presentation, dated May 2026 and labeled as Exhibit 99.1, may be used by management in future meetings to discuss the company.
The company states that the presentation includes a slide titled “Forward-Looking Statements” for important cautionary information. AEON also clarifies that the materials furnished under Item 7.01, including Exhibit 99.1, are not deemed filed under the securities laws and are not automatically incorporated into other SEC filings.